Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06578507

Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease

The purpose of this interventional, phase II, national, multicentric, non-randomised, open-label study is to evaluate the pharmacokinetics (PK), efficacy and safety of Hydroxycarbamide Paediatric dispersible tablets with a twice daily dosing regimen in children with Sickle Celle Disease between 9 months to 11 years of age.

Participants will:

* Take Hydroxycarbamide twice a day every day for 12 months * Visit the clinic at screening, baseline, 1, 3, 6, 9 and 12 months

Recruiting

Interested in participating?

Request Info

Key information

Age range

9 month–11 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Centre Hospitalier Intercommunal Créteil, Créteil, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent, signed and dated by both parents or by the legally acceptable representative(s) of the children, and, if possible, assent from the children,
  • HbSS or HbSβ0 SCD,
  • Aged between 9 months and 11 years old,
  • Hydroxycarbamide naïve,
  • Parent(s) or legally acceptable representative(s) capable of communicating with the investigator and understanding the requirements and constraints of the study protocol and willing to comply with the study requirements,
  • Contraception criterion, if applicable: for patients who are sexually active
  • Affiliated to a social security plan or beneficiary of a similar insurance plan,
  • Patient must meet the following laboratory values : Absolute Neutrophil Count ≥ 1.0x109/L, Platelets ≥ 75x109/L and Haemoglobin (Hgb) > 5.5 g/dL,
  • Transcranial Doppler (TCD) in the last 12 months indicating low risk for stroke is required for children over 18 months of age.

Exclusion criteria

  • Participation in any other clinical study for any other pharmaceutical product within 4 weeks preceding the inclusion visit,
  • Patients who have had chronic blood transfusion or transfusion in the last 3 months preceding the inclusion visit,
  • Patients treated with other SCD-modifying therapies,
  • Patient with a stage 3, 4 or 5 chronic kidney disease,
  • Patients known to be infected with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus,
  • Known hypersensitivity or allergy to the excipients,
  • Any surgical or medical condition or any significant illness that, in the opinion of the investigator, constitutes a risk or a contraindication to the participation of the patient to the study, or that may interfere with the objectives, conduct or evaluation of the study,
  • Female patients who are pregnant or lactating,
  • Any documented history of a clinical stroke or intracranial haemorrhage, or an uninvestigated neurologic finding within the past 12 months.

Treatment and study plan

Hydroxycarbamid

Drug

Hydroxycarbamide Paediatric dispersible tablets will be provided in the form of film-coated dispersible tablets containing 50 mg of hydroxycarbamide.

The IMP will be administered as half-strength twice daily, based on the body weight of the patient.

Other names: Hydroxyurea

Primary outcomes

  1. Evaluate the PK exposure for Hydroxycarbamide Paediatric dispersible tablets administered BID through area under the curve (AUC)

    Time frame: 1, 3, 6, 9 and 12 months after treatment initiation

  2. Evaluate the PK exposure for Hydroxycarbamide Paediatric dispersible tablets administered BID through time to obtain the maximum concentration (Tmax)

    Time frame: 1, 3, 6, 9 and 12 months after treatment initiation

  3. Evaluate the PK exposure for Hydroxycarbamide Paediatric dispersible tablets administered BID through maximum plasma concentration (Cmax)

    Time frame: 1, 3, 6, 9 and 12 months after treatment initiation

Secondary outcomes

  1. Absolute mean change from baseline in HbF levels

    Time frame: Baseline, 3, 6, 9 and 12 months after treatment initiation

  2. HC plasma concentrations and HbF levels

    Time frame: Baseline, 3, 6, 9 and 12 months after treatment initiation

  3. Daily AUC (AUC0-24h) at maintenance dose derived from the final PPK model

    Time frame: Baseline, 3, 6, 9 and 12 months after treatment initiation

  4. Proportion of patients with a relative difference in Cmax ≥ 30% from BID maintenance dose relative to the one simulated on a once daily regimen giving an equivalent AUC0-24h.

    Time frame: Baseline, 3, 6, 9 and 12 months after treatment initiation

  5. Absolute mean change from baseline in haematological parameters

    Time frame: Baseline,1, 3, 6, 9 and 12 months after treatment initiation

  6. Acceptability score based on a hedonic face scale evaluated by the child from 3 years old

    Time frame: 3 months after treatment initiation

  7. Acceptability score based on a 5-point Likert scale evaluated by the parent(s) or legally acceptable representative(s)

    Time frame: 3 months after treatment initiation

  8. Distribution of the scores related to the ease of using the administration kit for treatment administration to the child based on a 5-point Likert scale evaluated by the parent(s) or legally acceptable representative(s)

    Time frame: 3 months after treatment initiation

    Score 1 : very difficult to score 5 : very easy

  9. Compliance with Hydroxycarbamide Paediatric dispersible tablets administered BID by treatment unit accountability calculated by the pharmacy (patient will bring the kits with used and unused bottles to the pharmacy at each visit)

    Time frame: Baseline, 1, 3, 6, 9, 12 months after treatment initiation

  10. Number of SCD events occurring during the study

    Time frame: Baseline, 1, 3, 6, 9, 12 months after treatment initiation

  11. Number of adverse events (AEs) and percentage of patients reporting at least one AE

    Time frame: Baseline, 1, 3, 6, 9, 12 months after treatment initiation

Study contacts

Contact information is provided by the study sponsor or research team.

Laura Thomas-bourgneuf

CONTACT

[email protected]

+ 33 1 49 70 95 83

Nesrine Flissi

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Theravia

Industry

Registry information

Official study title

Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease: a Single-group, Non-randomised, Open-label Study (KID-BID)

Acronym: KID-BID

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Aug 29, 2024
Registry last updated
Sep 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.